Close Menu

NEW YORK (GenomeWeb) — The Translational Genomics Research Institute and Northern Arizona University have been jointly awarded a US patent for an allele-specific, real-time PCR-based assay to detect H1N1 pandemic flu and resistance to antiviral treatments.

With the patent in hand, TGen and NAU are now seeking a commercial partner to bring the assay to market, where it may prove useful in diagnosing H1N1 flu and determining whether it is resistant to commonly used antiviral treatments such as adamantane derivatives and oseltamivir, marketed as Tamiflu by Roche.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.